Theranostic Nanosensitizers for Highly Efficient MR/fluorescence Imaging-guided Sonodynamic Therapy of Gliomas
Overview
Molecular Biology
Authors
Affiliations
Glioma is the most frequent primary brain tumour of the central nervous system. Its high aggressiveness and deep-seated brain lesion make it a great challenge to develop a non-invasive, precise and effective treatment approach. Here, we report a multifunctional theranostic agent that can integrate imaging and therapy into a single nano-platform for imaging-guided sonodynamic therapy (SDT). The SDT agents were fabricated by encapsulation of sinoporphyrin sodium (DVDMS) chelating with manganese ions into nanoliposomes (DVDMS-Mn-LPs). DVDMS-Mn-LPs are physiologically stable and biologically compatible, and they can produce singlet oxygen upon ultrasound irradiation to kill cancer cells. Both cell and animal studies demonstrated that SDT with DVDMS-Mn-LPs can significantly improve the antitumour growth efficiency even in the presence of skull. In addition, DVDMS-Mn-LPs are good for MR and fluorescence imaging. Thus, DVDMS-Mn-LPs reported here may provide a promising strategy for imaging-guided modality for glioma treatment.
Emerging nanoplatforms towards microenvironment-responsive glioma therapy.
Tripathy N, Sahoo L, Paikray S, Dilnawaz F Med Oncol. 2025; 42(2):46.
PMID: 39812745 DOI: 10.1007/s12032-024-02596-y.
Sonodynamic therapy for adult-type diffuse gliomas: past, present, and future.
Scanlon S, Shanahan R, Bin-Alamer O, Bouras A, Mattioli M, Huq S J Neurooncol. 2024; 169(3):507-516.
PMID: 39042302 DOI: 10.1007/s11060-024-04772-6.
Zhang Y, Luo Y, Zhao J, Zheng W, Zhan J, Zheng H Acta Pharm Sin B. 2024; 14(1):110-132.
PMID: 38239237 PMC: 10792979. DOI: 10.1016/j.apsb.2023.08.024.
Wu D, Chen X, Zhou S, Li B Front Immunol. 2023; 14:1241791.
PMID: 37731484 PMC: 10507261. DOI: 10.3389/fimmu.2023.1241791.
Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier.
Hersh A, Bhimreddy M, Weber-Levine C, Jiang K, Alomari S, Theodore N Cancers (Basel). 2022; 14(19).
PMID: 36230843 PMC: 9563027. DOI: 10.3390/cancers14194920.